BrainsWay Ltd.'s SEC filings document foreign private issuer current reports for a medical technology company focused on noninvasive neurostimulation for mental health disorders. Recent Form 6-K reports furnish press releases and investor materials covering Deep TMS commercialization, FDA-cleared indications, payer reimbursement policies, clinical data, financial results, operating guidance, and strategic investments in provider networks and related neurostimulation assets.
The filings also identify the company as a Form 20-F filer and reference registration statements on Form S-8 and Form F-3. Exhibits disclose capital-allocation activity, customer and reimbursement developments, risk-factor themes in investor materials, and formal updates on the business model built around leasing and selling Deep TMS systems.
Brainsway Ltd. reported the appointment of Kost Forer Gabbay & Kasierer, a certified public accounting firm in Israel and a member of Ernst & Young Global, as the companys independent auditors for 2025 and continuing until the next annual general meeting. The Board of Directors is authorized to set the auditors compensation. The filing records a vote tally of 19,070,493 and includes the signature of Ami Boehm.
Brainsway Ltd. submitted a Form 6-K reporting corporate documents and exhibits, and confirming it files annual reports on Form 20-F. The filing incorporates by reference the companys Registration Statement on Form S-8 (Registration No. 333-230979) and two Form F-3 registration statements (Registration Nos. 333-280934 and 333-286672) with respective filing dates of April 22, 2019, July 22, 2024, and April 22, 2025. An exhibit index lists a press release dated August 21, 2025, an Investment Agreement, a Call Option Agreement, Amended and Restated Articles of Association, and a Second Amended and Restated Investors Rights Agreement. The report is signed by Chief Executive Officer Hadar Levy.